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OBJECTIVE — We explored cognitive impairment in metabolic syndrome in relation to
brain magnetic resonance imaging (MRI) ﬁndings.
RESEARCH DESIGN AND METHODS — We studied 819 participants free of clinical
stroke and dementia of the population-based Austrian Stroke Prevention Study who had under-
gone brain MRI, neuropsychological testing, and a risk factor assessment relevant to National
CholesterolEducationProgramAdultTreatmentPanelIIIcriteria–deﬁnedmetabolicsyndrome.
High-sensitivity C-reactive protein (hs-CRP) was also determined.
RESULTS — Of 819 subjects, 232 (28.3%) had metabolic syndrome. They performed worse
than those without metabolic syndrome on cognitive tests assessing memory and executive
functioning after adjustment for possible confounders. Stratiﬁcation by sex demonstrated that
metabolicsyndromewasrelatedtocognitivedysfunctioninmenbutnotinwomen.Onlyinmen
was an increasing number of metabolic syndrome components associated with worse cognitive
performance. MRI showed no signiﬁcant differences in focal ischemic lesions and brain volume
betweensubjectswithandwithoutmetabolicsyndrome,andMRIabnormalitiesfailedtoexplain
impaired cognition. Cognitive performance was most affected in male subjects with metabolic
syndrome who also had high hs-CRP levels.
CONCLUSIONS — Metabolic syndrome exerts detrimental effects on memory and execu-
tive functioning in community-dwelling subjects who have not had a clinical stroke or do not
have dementia. Men are more affected than women, particularly if they have high inﬂammatory
markers. MRI-detected brain abnormalities do not play a crucial role in these relationships.
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M
etabolic syndrome is a cluster of
cardiovascular risk factors, in-
cluding abdominal obesity,
atherogenic dyslipidemia, raised blood
pressure, and insulin resistance and glu-
cose intolerance (1). It has been associ-
ated with cognitive dysfunction (2,3) and
Alzheimer’s disease (4), but data are dis-
cordant(5–7).Negativeassociationswere
reportedwithmemory,processingspeed,
and ﬂuid intelligence (3). Impaired cog-
nition was linked to high-level inﬂamma-
tion (2).
Although components of the meta-
bolic syndrome have been individually
related to cognitive outcomes, the mech-
anisms affecting cognition in metabolic
syndrome are undetermined. Factors re-
lated to peripheral hyperinsulinemia are
probably highly relevant. Peripheral hy-
perinsulinemia downregulates blood-
brain barrier insulin receptors and
subsequently reduces insulin transport to
the brain followed by decreased acetyl-
choline neurotransmission and cerebral
blood ﬂow (8). In addition, hyperglyce-
mia itself contributes to neuronal apopto-
sis via increased generation of free
radicals, enhanced glycation end prod-
ucts, and elevated lipid peroxidation (8).
Interactiveeffectsbetweenhyperglycemia
and components of metabolic syndrome
such as arterial hypertension have been
reported (9). Another possible mecha-
nism are vascular lesions as a sequela of
components of metabolic syndrome in-
cluding hypertension, impaired glucose
tolerance, and dyslipidemia. Previous
magnetic resonance imaging (MRI) stud-
ies described higher rates of silent brain
infarcts(10)andleukoaraiosis(11).Adif-
fusion tensor imaging study found evi-
dence for ultrastructural tissue damage in
frontal and temporal lobes (12). These
studies did not include cognitive testing
and thus cannot imply the higher fre-
quency of brain lesions to be responsible
formetabolicsyndrome–relatedcognitive
dysfunction.
Weevaluatedbothcognitivefunction
and brain MRI-detected lesions in a large
cohort of community-dwelling subjects.
We hypothesize that individuals with
metabolic syndrome have global and do-
main-speciﬁc cognitive dysfunction, a
higher frequency of brain abnormalities,
and a cognitive status that relates to brain
MRI ﬁndings.
RESEARCH DESIGN AND
METHODS— The Austrian Stroke
Prevention Study (ASPS) is a prospective
studyontheeffectsofvascularriskfactors
on brain structure and function in cogni-
tively normal middle-aged and elderly in-
habitants of Graz, Austria; details have
been previously described (13,14).
Brieﬂy,2,007participantswererandomly
selected from the ofﬁcial community reg-
ister, and all participants were free of
stroke and dementia. The study protocol
was approved by the responsible ethics
committee.
In a ﬁrst study panel between 1991
and 1994, 509 subjects randomly se-
lected from the entire cohort underwent
an extended diagnostic work-up includ-
ing brain MRI and cognitive testing. To
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ropsychological assessments, an addi-
tional 567 individuals were randomly
selected in a second panel between 1999
and 2003. They underwent identical im-
aging and cognitive test procedures. Par-
ticipants of the ﬁrst and second panels
were pooled, which resulted in a total of
1,076 individuals with brain MRI and
neuropsychological evaluation. The long
diagnostic periods resulted from limited
research-devoted time slots at the MRI
center. All clinical examinations were re-
peated with MRI scanning and neuropsy-
chological testing. Clinical history, blood
tests, MRI, and cognitive assessments
were always done in 1 day. A total of 819
subjectshadacompleteriskfactorassess-
ment necessary to determine metabolic
syndrome and thus created the current
study cohort.
Risk factors and deﬁnition of
metabolic syndrome
Risk factors were determined based on
history and measurements at the exami-
nation, as previously described (13). Hy-
pertension was considered a history of
hypertension with repeated blood pres-
surereadings140/90mmHg,treatment
forhypertension,orreadingsattheexam-
ination exceeding the limit. Diabetes was
coded present if an individual was treated
for diabetes at the time of examination or
if the fasting blood glucose level at the
examinationexceeded126mg/dl.History
of coronary heart disease was determined
accordingtotheRosequestionnaire,atrial
ﬁbrillation was diagnosed based on elec-
trocardiogram ﬁndings, and peripheral
artery disease was diagnosed based on
history. Study participants were asked
whether they were previous and/or cur-
rent smokers or habitual daily drinkers as
well as about their physical activity at lei-
sure time; the amount of activity was
graded into none (no physical activity),
mild (daily walk), and moderate to inten-
sive (daily sports). Waist circumference
was measured to deﬁne central obesity. A
lipid status was determined with stan-
dardized measurements for each study
participant after a 12-h fasting. High-
sensitivity C-reactive protein (hs-CRP)
was measured with a particle-enhanced
immunoturbimetric assay, with a detec-
tion limit of 0.1 mg/l. We deﬁned a high
level of inﬂammation as hs-CRP levels
above the median of hs-CRP distribution
(1.9 mg/l) in our cohort.
Metabolic syndrome was deﬁned ac-
cording to National Cholesterol Educa-
tion Program Adult Treatment Panel III
criteria and revised American Heart Asso-
ciation/National Heart, Lung, and Blood
Institute criteria (1). Participants were
consideredtohavemetabolicsyndromeif
they met three or more of the following
criteria: 1) waist circumference 102 cm
in men and 88 cm in women, 2) fasting
serum triglycerides 150 mg/dl or treat-
ment for hypertriglyceridemia, 3) serum
HDL cholesterol 40 mg/dl in men and
50mg/dlinwomenortreatmentforlow
HDL cholesterol, 4) blood pressure
130/85 mmHg or use of antihyperten-
sive drugs, 5) fasting blood glucose levels
110 mg/dl or use of antidiabetes drugs.
Neuropsychological testing
A test battery assessing memory and
learningabilities,psychomotorskills,and
executive functions was administrated as
described previously (13,14). To assess
learningabilityandintermediatememory
recall, one test called Ba ¨umler’s Lern und
Geda ¨chtnistest was used. Psychomotor
skillswereevaluatedbyonetestcalledthe
Purdue’s Pegboard Test. Executive func-
tions were assessed by three tests: the
WisconsinCardSortingTest,partBofthe
Trail Making Test, and Digit Span Back-
wards, which is part of the Wechsler
AdultIntelligenceScale,revised.Weused
summary measures of cognitive function
by converting individual test results to z-
scores and computing the average of
the scores within each cognitive domain.
Z-scores were not adjusted for age, sex,
and education. For assessment of depres-
sive mood we applied the “Eigen-
schaftswo ¨rterliste” of W. Janke, G. Debus
(1978) Die Eigenschaftswo ¨rterliste (EWL);
Handanweisung, Go ¨ttingen: Hogrefe, a
validated multidimensional tool consist-
ing of a list of given adjectives describing
theemotionalstatusofatestpersonatthe
time of the interview.
MRI
All scans were obtained on a 1.5-Tesla
scanner (Philips Medical Systems, Eind-
hoven, The Netherlands) with protocols
described previously (13). White matter
lesion(WML)volume,lacunes,thrombo-
embolic infarcts, and brain volume were
determined in each study participant.
WML volume
The scans were analyzed by two experi-
enced investigators (C.E. and R.S.). They
ﬁrst graded WMLs according to our
scheme (15), then marked and outlined
each WML on a transparency that was
overlaid on the proton density scans.
They were blinded to clinical data of
study participants. Independently from
this visual analysis, lesion load measure-
ments were done on proton density–
weighted images on an UltraSPARC
workstation (Sun Microsystems, Santa
Clara, CA) by a trained operator using
DISPImage (16). The trained operator
used a hardcopy overlaid by the transpar-
ency, with all lesions outlined by the ex-
perienced readers as reference, and
segmented all lesions on the computer
image. Lesion areas were then provided
by the semiautomated thresholding algo-
rithm implemented in DISPImage. The
total lesion volume (cm
3) was calculated
by multiplying the total lesion area by
slice thickness.
Lacunes and thromboembolic
infarcts
Lacunes were deﬁned as focal lesions that
involved the basal ganglia, internal cap-
sule,thalamus,orbrainstem,notexceed-
ing a maximum diameter of 15 mm. The
presence of silent thromboembolic in-
farcts was also recorded.
Brain volume
Brain volume was calculated from the T2-
weighted spin echo sequence using the
fully automated structural image evalua-
tionofatrophy(Sienax,partoftheFMRIB
Software Library; http://www.fmrib.ox.
ac.uk/fsl). Brain parenchyma percentage
was estimated from the ratio of parenchy-
mal volume to the total volume given by
the outer surface of the brain. To deter-
minethemeasurementerrorsinourdata-
set, 20 participants were scanned and
rescanned after shortly leaving the scan-
ner. The median relative error for Sienax
was 1.2%.
Data analysis
Signiﬁcant differences in means of nor-
mally distributed continuous variables
were tested by ANOVA and signiﬁcant
differences of nonnormally distributed
variables by the Mann-Whitney U test.
Differenceinproportionswasassessedby

2 statistics.
Linear regression analysis was per-
formed to estimate the association be-
tween metabolic syndrome and the
z-scoresofthespeciﬁccognitivedomains.
Different models were assessed. Model 1
included age and sex plus subjects’ char-
acteristics that were different across the
metabolic syndrome, including years of
education, leisure physical activity, and
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cantly more common in patients with
metabolic syndrome, hypertension and
diabetes were not used as covariates be-
cause all subjects with hypertension and
diabetes were included in our deﬁnition
of metabolic syndrome. Depressive mood
was considered as a covariate based on its
signiﬁcant relationship to cognitive func-
tioning. Model 2 investigated to what ex-
tent the associations between metabolic
syndrome and cognition were mediated
by MRI ﬁndings and thus included all co-
variates of model 1 plus presence of la-
cunes, silent infarcts, WML volume, and
brain parenchymal fraction. The relation-
ship between metabolic syndrome and
vascular lesions and brain atrophy was
determined by multivariate regression
analyses using model 1 covariates.
Multicollinearity between MRI vari-
ables was assessed using the variance in-
ﬂation factor (VIF). Usually, VIF values
10 are suggestive of multicollinearity
andmeritfurtherinvestigation.Themean
VIF for MRI variables in our study was
1.04 (range 1.01–1.08). Because data
from the literature suggest possible sex
differencesinmetabolicsyndrome(6,17),
we also stratiﬁed our analyses by sex.
Hs-CRP measurements were available
in only a subset of our cohort, thus we did
notincludethisfactorintheprimarymodel
butperformedasubanalysisin541subjects
with hs-CRP measurement to assess
whetherinﬂammationplaysacausalrolein
the association between metabolic syn-
drome and cognition. This subanalysis was
done with and without additional adjust-
ment for nonsteroidal anti-inﬂammatory
drugs or acetylsalicyclic acid use. Interac-
tions of hs-CRP and metabolic syndrome
with cognitive functioning were tested by
including the respective interaction term in
the multivariate linear regression models.
All analyses were done using Stata (Stata
Statistical Software, release 6; StataCorp,
College Station, TX).
RESULTS— A total of 232 (28.3%)
study participants had metabolic syn-
drome. There were 157 (67.6%) subjects
with three, 55 (23.7%) with four, and 20
(8.6%) with ﬁve components of meta-
bolicsyndrome.Thecharacteristicsofthe
study cohort are shown in Table 1. Sub-
jects with metabolic syndrome had lower
educational status, less leisure physical
activity, more coronary heart disease,
higher frequencies of each component of
metabolic syndrome, and higher hs-CRP.
Table 2 shows that subjects with met-
abolic syndrome performed worse on all
cognitive tests, with signiﬁcant differences
in memory and executive functions, but
there existed no signiﬁcant differences in
MRI ﬁndings between subjects with and
without metabolic syndrome. Metabolic
syndrome and MRI ﬁndings were also not
signiﬁcantly associated in multivariate re-
gression analyses (data not shown).
Whenusinglinearregressionanalysis
with adjustment for age, sex, years of ed-
ucation, depressive mood, coronary heart
disease, and physical activity at leisure
time (Table 3, model 1), the inverse asso-
ciations between metabolic syndrome
and memory, as well as executive func-
tions, remained signiﬁcant. The results
were virtually unchanged following ad-
justmentforMRIﬁndings(Table3,model
2).Stratiﬁcationbysexdemonstratedthat
the signiﬁcant relationship between met-
abolic syndrome and impaired memory
and executive functioning existed only in
men but not in women (Table 3).
Figure 1 displays the relationship be-
tween the number of components of met-
abolic syndrome and performance on
tests of memory and executive function-
ing. In men, with more components of
metabolic syndrome present, memory
(one component:  0.38; two com-
ponents:  0.52; three components:
 0.64; more than three compo-
nents:  0.71; P for trend 0.001)
and executive functions (one component:
 0.99; two components: 
1.02; three components:  1.55;
morethanthreecomponents:1.90;P
fortrend0.010)weremoreimpaired.No
such relationship existed in women.
A multivariate regression analysis ad-
justed for model 1 and 2 covariates
showed that men, but not women, with
metabolic syndrome who had high hs-
CRP levels (i.e., 1.9 mg/l) performed
signiﬁcantly worse on tests of memory
( 0.44; 95% CI [0.94 to 0.04];
P  0.074) and executive functions (
Table1—Characteristicsofthestudycohort(n819)bytheabsenceorpresenceofmetabolic
syndrome
Variable
No metabolic
syndrome
Metabolic
syndrome P
n 587 232
Demographic characteristics
Age (years) 64.8  8.1 65.1  7.2 0.64*
Women 318 (54.1) 138 (59.5) 0.16†
Years of education 10 (9–13) 10 (9–10) 0.002‡
Risk factors
Smoking status 0.44†
Never 361 (61.5) 133 (57.3)
Former 163 (27.8) 68 (29.3)
Current 63 (10.7) 31 (13.4)
Daily alcohol consumption 75 (16.4) 36 (19.8) 0.30†
Physical activity at leisure time 0.008†
None 31 (5.3) 26 (11.2)
Mild 189 (32.2) 76 (32.7)
Moderate to intensive 367 (62.5) 130 (56.1)
Hypertension 391 (66.6) 202 (87.1) 0.001†
History of coronary heart disease 183 (31.2) 89 (38.9) 0.051†
Diabetes 15 (2.6) 56 (24.2) 0.001†
Atrial ﬁbrillation 12 (2.0) 4 (1.7) 0.77†
Peripheral arterial disease 5 (0.9) 5 (2.3) 0.13†
Depressive mood 1 (0–2) 1 (0–2) 0.92‡
hs-CRP (mg/l)§ 1.7 (0.8–3.2) 2.5 (1.4–5.1) 0.001‡
Components of metabolic syndrome
Abdominal obesity 149 (25.3) 176 (75.8) 0.001‡
Triglycerides 150 mg/dl 76 (12.9) 172 (74.1) 0.001†
Low HDL cholesterol 64 (10.9) 133 (57.3) 0.001†
Fasting glucose 110 mg/dl 25 (4.2) 84 (36.2) 0.001†
Blood pressure 130/85 mmHg 467 (79.5) 226 (97.4) 0.001†
DataaremeansSD,n(%),ormedian(interquartilerange).*ANOVAtest.†
2test.‡Mann-WhitneyUtest.
§Measurement of hs-CRP only available in 541 subjects.
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0.007) than their male counterparts with
low hs-CRP (memory:  0.05; 95%
CI [0.45 to 0.33]; P  0.774; executive
functions: 0.48; 95% CI [0.74 to
1.7]; P  0.437). After adjustment for
nonsteroidal anti-inﬂammatory drugs or
aspirin usage in the model, the results re-
mained almost identical (data not
shown). The interaction between hs-CRP
and metabolic syndrome was signiﬁcant
for executive functions ( 2.79; 95%
CI [4.67 to 0.92]; P  0.004) and
showed a nonsigniﬁcant trend for mem-
ory(0.56;95%CI[1.17to0.04];
P  0.068).
CONCLUSIONS — Middle-agedand
elderly community-dwelling subjects
with metabolic syndrome performed
worse on tasks assessing memory and ex-
ecutive functions than their counterparts
without metabolic syndrome. This was
seen in men but not in women, and the
morecomponentsofmetabolicsyndrome
werepresent,themoreimpairedwascog-
nitivefunctioning.Focalanddiffusebrain
lesions failed to explain the association
between metabolic syndrome and cogni-
tion. Men with metabolic syndrome and
high inﬂammatory markers had more se-
vere cognitive deﬁcits.
Previous studies (2,3) described cog-
nitive dysfunction in patients with meta-
bolic syndrome. Most used gross
measures of cognition for patients’ assess-
ment (2). The Longitudinal Aging Study
Amsterdam also applied comprehensive
neuropsychologicaltestingand,similarto
us, also found memory and processing
speed deﬁcits in metabolic syndrome pa-
tients(3).Thispatternfavorsbothcortical
and subcortical brain damage as the un-
derlyingcause(18).Ourﬁndingthatmet-
abolic syndrome affects cognition,
particularly in men, is novel. So far, only
fewstudiesstratiﬁedtheiranalysesbysex,
and they yielded conﬂicting results. Van-
hanen et al (4) found more Alzheimer’s
disease in metabolic syndrome patients,
and, after stratiﬁcation by sex, this asso-
ciation existed predominantly in women.
By contrast, Laudisio et al. (6) reported
that female patients performed cogni-
tively better than male patients. So far,
sex-speciﬁc differences in risk factor–
related biological mechanisms leading to
cognitive decline remained widely unex-
plored. We can only speculate on the
causes for more pronounced cognitive
deﬁcits in men than in women with met-
abolic syndrome. Central nervous insulin
resistancemayplayarole.Itisassumedto
be a common denominator of metabolic
disorders and cognitive dysfunctions by
exerting detrimental effects on cholin-
ergic and glutamatergic pathways which
establish neuronal plasticity (19).
Women have less insulin resistance
Table 2—Cognitive performance and brain MRI ﬁndings in the sample (n  819) by the absence or presence of metabolic syndrome
Variable No metabolic syndrome Metabolic syndrome P
n 587 232
Neuropsychological test results
Mini Mental State Examination 27.5  1.5 (22–30) 27.4  1.5 (22–30) 0.58*
Memory 0.06  1.0 (1.91 to 4.38) 0.17  0.9 (1.98 to 3.32) 0.001*
Psychomotor skills 0.06  0.8 (3.00 to 2.56) 0.01  0.9 (2.17 to 2.93) 0.46*
Executive functions 0.49  3.0 (18.23 to 5.44) 0.32  3.1 (16.04 to 5.21) 0.001*
Brain MRI ﬁndings
WML volume in cm
3 0.9 (0.2–3.1) 0.9 (0.2–2.4) 0.89†
Lacunes 32 (5.4) 15 (6.4) 0.56‡
Silent infarcts 16 (2.7) 10 (4.3) 0.24‡
Normalized brain percentage 0.78  0.03 (0.67–0.87) 0.78  0.04 (0.68–0.86) 0.38*
Data are means  SD (range), n (%), or median (interquartile range). *ANOVA test. †Mann-Whitney U test. ‡
2 test.
Table 3—Relationship between metabolic syndrome and cognition: multivariate regression analysis
Model 1*
Total sample (n  819)† Men (n  363) Women (n  456)
 P 95% CI  P 95% CI  P 95% CI
Memory 0.14 0.034 0.27 to 0.01 0.27 0.013 0.49 to 0.05 0.06 0.444 0.22 to 0.09
Psychomotor skills 0.03 0.593 0.14 to 0.08 0.09 0.280 0.26 to 0.07 0.03 0.670 0.11 to 0.17
Executive functions 0.58 0.010 1.02 to 0.14 0.80 0.033 1.54 to 0.06 0.39 0.162 0.94 to 0.15
Model 2*
Total sample (n  819)† Men (n  363) Women (n  456)
 P 95% CI  P 95% CI  P 95% CI
Memory 0.12 0.090 0.27 to 0.02 0.25 0.050 0.51 to 0.00 0.04 0.645 0.23 to 0.14
Psychomotor skills 0.006 0.920 0.13 to 0.11 0.02 0.842 0.18 to 0.22 0.003 0.961 0.16 to 0.15
Executive functions 0.65 0.010 1.14 to 0.15 0.94 0.023 1.74 to 0.13 0.44 0.165 1.07 to 0.18
*Model 1: adjusted for age, years of education, depressive mood, coronary heart disease, and physical activity at leisure time. Model 2: model 1 plus adjustment for
WML volume, presence of lacunes, silent infarcts, and brain parenchymal fraction. †Total sample: additionally adjusted for sex.
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to metabolic syndrome–related cognitive
dysfunction. Several mechanisms have
been reported, leading to a more insulin-
sensitive environment in women. These
include sex differences in adipose tissue
distribution, estrogen effects on insulin
and glucose homeostasis and proinﬂam-
matorymarkers,aswellashigherlevelsof
the insulin-sensitizing hormone adi-
ponectin in women (20).
We saw no signiﬁcant differences in
ischemic brain lesions or brain atrophy
between subjects with and without meta-
bolic syndrome. Our MRI results were
unexpected, as previous investigations
described associations of metabolic syn-
drome with increasing grades of white
matter abnormalities (11) and brain in-
farctions (10), and several studies indi-
cated more pronounced brain atrophy in
individuals with single components of
metabolicsyndromesuchasdiabetes(21)
and hypertension (22). We probably re-
cruited healthier participants than previ-
ous hospital- or population-based
cohorts not excluding clinically overt ce-
rebral disease (10,11). It remains to be
determinedwhetherultrastructuraltissue
changes in subcortical or cortical tissue
compartments not seen in conventional
but new MRI techniques, such as diffu-
sion tensor imaging (12), occur with met-
abolic syndrome and whether they
correlate with cognitive decline.
Our analyses on the associations be-
tween metabolic syndrome, hs-CRP lev-
els,andcognitivefunctioningsuggestthat
inﬂammation interacts in the relationship
between metabolic syndrome and cogni-
tive impairment. This ﬁnding is corrobo-
rated by investigations by Dik et al. (3)
and Yaffe et al. (2,23) that described the
detrimental effect of metabolic syndrome
on cognition mainly in metabolic syn-
drome subjects with high levels of proin-
ﬂammatory markers. The association
between hs-CRP and cognitive impair-
mentinmetabolicsyndromepatientsmay
at ﬁrst seem to indicate that subjects with
ongoing generalized atherosclerosis are at
greaterriskofconcurrentandsubsequent
cerebrovasculardamageandneurodegen-
eration,bothofwhichcausecognitivede-
cline. This, however, is unlikely based on
our ﬁndings that the frequency of focal
ischemic lesions and brain atrophy was
similar in subjects with and without met-
abolic syndrome, and MRI abnormalities
were not related to cognitive test perfor-
mance. These ﬁndings rather favor in-
ﬂammatory processes being directly
related to both metabolic syndrome and
Figure 1—Relationship between memory performance (upper panel), executive functions (lower panel), and number of metabolic syndrome
components (indicated on the y-axis in the middle). Multivariate regression analysis stratiﬁed by sex and adjusted for age, years of education,
depressivemood,physicalactivityatleisuretime,andcoronaryheartdisease.Thesquaresonthex-axisindicate-coefﬁcients,andthebarsindicate
95% CIs. An increasing number of metabolic syndrome components was associated with worse function in these domains in men only.
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their possible role in the etiology of vas-
cular and primary degeneration. In-
creased hs-CRP levels may well reﬂect
lifetime overreactivity of the innate im-
mune system to various exogenous and
endogenous stimuli. This overreactivity
maybegeneticallydeterminedandconfer
the increased risk for developing both
metabolic syndrome and cognitive im-
pairment in later life. Consequently, the
interactive association observed here of
metabolic syndrome and hs-CRP with cog-
nitive functions is of particular interest. In
this context it is also noteworthy that ele-
vated levels of inﬂammatory markers have
been repeatedly linked to an increased risk
of dementia (23). Intriguingly, the Hono-
lulu Asia Aging Study reported increased
hs-CRP levels 25 years prior to the occur-
rence of dementia (24). Similar data come
from the Rotterdam Study (25).
A strength of our study is the simul-
taneous assessment of cognitive function
and brain MRI in a large cohort of com-
munity-dwelling subjects who were pro-
spectively examined using a standardized
protocol. An important limitation of this
study is its cross-sectional design, which
does not permit to deduce a cause-and-
effect relationship. Other limitations include
missing measurements of hippocampal
volume due to lack of coronal MRI se-
quences and missing information on du-
ration of metabolic syndrome. The
cognitive deﬁcits observed in our study
are subtle and clinically covert. Their pre-
dictive implications require long-term
longitudinal evaluation. Sex-speciﬁc ef-
fects associated with proinﬂammatory
markers and the lack of signiﬁcant asso-
ciations with MRI abnormalities ought to
be considered in future studies on mech-
anisms of cognitive impairment in meta-
bolic syndrome.
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